AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22403352 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile cardiopulmonary bypass
Number of subjects: 33
Study 20157671 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental primers with RRP fillers (various combinations of MPS, BMEP, and EGMP)
Number of subjects: 0
Study 20157671 — intervention group
Group type: COMPARATOR
Intervention: Commercial etch-and-rinse adhesive (control)
Number of subjects: 0
Study 18576902 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal haloperidol 2.5 mg (2.5 mg/0.1‐ml spray into a single naris)
Number of subjects: 4
Study 18576902 — intervention group
Group type: COMPARATOR
Intervention: Intravenous haloperidol 2.5 mg (0.5 ml of 5.0 mg/ml) infused over 15 minutes
Number of subjects: 4
Study 18576902 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol 2.5 mg (0.5 ml of 5.0 mg/ml)
Number of subjects: 4
Study 18576902 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal haloperidol 2.5 mg
Number of subjects: 4
Study 18576902 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal haloperidol
Number of subjects: 4
Study 16278497 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (Enbrel) in phase IV community cohort study
Number of subjects: 0
Study 16278497 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (Enbrel) in phase III RCTs
Number of subjects: 0
Study 16278497 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based patients
Number of subjects: 0
Study 16278497 — intervention group
Group type: COMPARATOR
Intervention: RCT patients
Number of subjects: 0
Study 12425705 — intervention group
Group type: EXPERIMENTAL
Intervention: GH + HRT
Number of subjects: 131
Study 12425705 — intervention group
Group type: EXPERIMENTAL
Intervention: GH
Number of subjects: 131
Study 12425705 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 131
Study 12425705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 12425705 — intervention group
Group type: EXPERIMENTAL
Intervention: GH + testosterone
Number of subjects: 131
Study 12425705 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 131
Study 10420094 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 4‐10 (1 mg)
Number of subjects: 54
Study 10420094 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 4‐10 (1 mg/day over 6 weeks)
Number of subjects: 54
Study 10420094 — intervention group
Group type: EXPERIMENTAL
Intervention: Desacetyl‐α‐MSH (1.68 mg)
Number of subjects: 54
Study 10420094 — intervention group
Group type: EXPERIMENTAL
Intervention: Desacetyl‐α‐MSH (subchronic treatment)
Number of subjects: 54
Study 8937121 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (30 mg, p.o., qam, daily for 6 weeks)
Number of subjects: 63
Study 8937121 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg, p.o., qam, daily for 6 weeks) plus Amoxicillin (1500 mg, p.o, t.i.d., daily for 2 weeks)
Number of subjects: 63
Study 8937121 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole and Amoxicillin combination
Number of subjects: 63
Study 1877125 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene (Gore‐Tex) sutures
Number of subjects: 24
Study 1877125 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene (Prolene) sutures
Number of subjects: 24
Study 7049204 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mexiletine
Number of subjects: 216
Study 7049204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 31243156 — intervention group
Group type: EXPERIMENTAL
Intervention: Population health intervention involving a clinical pharmacist reviewing charts and contacting primary care providers for anticoagulation management.
Number of subjects: 432
Study 31243156 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 432
Study 30277547 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy frame
Number of subjects: 183
Study 30277547 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient management frame
Number of subjects: 183
Study 30277547 — intervention group
Group type: COMPARATOR
Intervention: Control frame
Number of subjects: 183
Study 27571387 — intervention group
Group type: EXPERIMENTAL
Intervention: New participatory, supportive return-to-work program
Number of subjects: 186
Study 27571387 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 186
Study 24820727 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 171
Study 24820727 — intervention group
Group type: COMPARATOR
Intervention: Nasal endotracheal intubation (ET)
Number of subjects: 171
Study 22286364 — intervention group
Group type: COMPARATOR
Intervention: Calcium-modified orange juice (1.6 g/l of calcium) (C+)
Number of subjects: 10
Study 22286364 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice with 0.4 g/l of calcium from calcium lactate pentahydrate (Ca)
Number of subjects: 10
Study 22286364 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice with 0.2 g/l of linear sodium polyphosphate (LPP)
Number of subjects: 10
Study 22286364 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of calcium and LPP (Ca+LPP)
Number of subjects: 10
Study 22286364 — intervention group
Group type: COMPARATOR
Intervention: Commercially available orange juice (negative control, C-)
Number of subjects: 10
Study 20133491 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (2 mg)
Number of subjects: 149
Study 20133491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 17377905 — intervention group
Group type: EXPERIMENTAL
Intervention: 3F-CVVH (high-adsorption hemofiltration)
Number of subjects: 12
Study 17377905 — intervention group
Group type: COMPARATOR
Intervention: 1F-CVVH (standard hemofiltration)
Number of subjects: 12
Study 17377905 — intervention group
Group type: COMPARATOR
Intervention: Control blood (1F-CVVH)
Number of subjects: 12
Study 15327134 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective alpha1A/D-adrenoblocker tamsulosin
Number of subjects: 0
Study 11593093 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (10%) in obese hypertensive subjects
Number of subjects: 52
Study 11593093 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 52
Study 11593093 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss maintenance period
Number of subjects: 52
Study 11593093 — intervention group
Group type: COMPARATOR
Intervention: Dietary fatty acid intervention
Number of subjects: 52
Study 9850939 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone 90 mg tid for 24 months
Number of subjects: 450
Study 9850939 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone 120 mg tid for 24 months
Number of subjects: 450
Study 9850939 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 months followed by idebenone 90 mg tid for another 12 months
Number of subjects: 450
Study 7989621 — intervention group
Group type: EXPERIMENTAL
Intervention: SofScale pre-scaling gel
Number of subjects: 31
Study 7989621 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 31
Study 3059235 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol 40 mg once daily
Number of subjects: 20
Study 3059235 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg once daily
Number of subjects: 20
Study 30830672 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal ctDCS (2.0 mA, 20 min per day, 5 days a week)
Number of subjects: 14
Study 30830672 — intervention group
Group type: COMPARATOR
Intervention: Sham ctDCS
Number of subjects: 14
Study 28426678 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education combined with food security activities
Number of subjects: 24
Study 28426678 — intervention group
Group type: COMPARATOR
Intervention: Food security activities only (Control)
Number of subjects: 24
Study 26216472 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple-to-complex training protocol
Number of subjects: 0
Study 26216472 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous training protocol
Number of subjects: 0
Study 23929580 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills course
Number of subjects: 60
Study 23929580 — intervention group
Group type: COMPARATOR
Intervention: Control group (no communication skills course)
Number of subjects: 60
Study 21726464 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors associated with microalbuminuria
Number of subjects: 886
Study 19332211 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal beta-blockade (UBB; n = 197) comprising an algorithm‐based, nurse‐led strategy to optimize dosing and adherence to bisoprolol titration over > or =1 week preoperatively
Number of subjects: 400
Study 19332211 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC; n = 203) whereby beta-blockers are continued in those already taking them or prescribed for patients identified as high risk based on ischemia
Number of subjects: 400
Study 15764956 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition with 10 mg of OX administered orally twice a day
Number of subjects: 50
Study 15764956 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition with progressive resistance training (PRT) for 12 weeks
Number of subjects: 50
Study 15764956 — intervention group
Group type: COMPARATOR
Intervention: Nutrition alone (NA) with placebo pills
Number of subjects: 50
Study 10486791 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined esterified estrogen-methyltestosterone therapy (0.625 mg esterified estrogen + 1.25 mg methyltestosterone or 1.25 mg esterified estrogen + 2.5 mg methyltestosterone)
Number of subjects: 641
Study 10486791 — intervention group
Group type: COMPARATOR
Intervention: Estrogen therapy alone
Number of subjects: 641
Study 7493415 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose phentolamine (0.3 +/- 0.1 degrees C)
Number of subjects: 10
Study 7493415 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose phentolamine (0.2 +/- 0.0 degrees C)
Number of subjects: 10
Study 7493415 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose phentolamine (0.1 +/- 0.0 degrees C)
Number of subjects: 10
Study 7493415 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose phentolamine (0.6 +/- 1 degrees C)
Number of subjects: 10
Study 7493415 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of phentolamine
Number of subjects: 10
Study 7493415 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium and high doses of phentolamine
Number of subjects: 10
Study 1903846 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugate vaccine consisting of H. influenzae type b polysaccharide and Neisseria meningitidis OMPC
Number of subjects: 5188
Study 1903846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5188
Study 1903846 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugate vaccine
Number of subjects: 5188
Study 6263476 — intervention group
Group type: EXPERIMENTAL
Intervention: HAM (hexamethylmelamine, doxorubicin, and methotrexate)
Number of subjects: 284
Study 6263476 — intervention group
Group type: COMPARATOR
Intervention: C (cyclophosphamide and CCNU)
Number of subjects: 284
Study 6263476 — intervention group
Group type: COMPARATOR
Intervention: Crossover therapy with VM‐26 or ascorbic acid
Number of subjects: 284
Study 30794296 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy exercise (n=96)
Number of subjects: 240
Study 30794296 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based group exercise (n=96)
Number of subjects: 240
Study 30794296 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control arm, n=48)
Number of subjects: 240
Study 29581079 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-sensitizing therapy (thiazolidinediones)
Number of subjects: 2319
Study 29581079 — intervention group
Group type: COMPARATOR
Intervention: Insulin-providing therapy (insulin, sulfonylurea, or a meglitinide)
Number of subjects: 2319
Study 29581079 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (while exposed)
Number of subjects: 2319
Study 29581079 — intervention group
Group type: COMPARATOR
Intervention: No exposure to thiazolidinediones
Number of subjects: 2319
Study 29581079 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset of patients matched on propensity to receive thiazolidinediones
Number of subjects: 2319
Study 27179166 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation with lifestyle modification
Number of subjects: 50
Study 27179166 — intervention group
Group type: COMPARATOR
Intervention: Placebo with lifestyle modification
Number of subjects: 50
Study 24188510 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 116
Study 24188510 — intervention group
Group type: COMPARATOR
Intervention: No specific control intervention mentioned
Number of subjects: 116
Study 21992111 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine fast titration (8 mg/week increments to 16-24 mg)
Number of subjects: 89
Study 21992111 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine slow titration (8 mg/4 weeks to 16-24 mg)
Number of subjects: 89
Study 21992111 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (both titration arms)
Number of subjects: 89
Study 20661022 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin
Number of subjects: 206
Study 20661022 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 206
Study 17156148 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of 6-methyl-prednisolone (1 mg/kg/day)
Number of subjects: 66
Study 17156148 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 6-methyl-prednisolone (1 mg/kg/day)
Number of subjects: 66
Study 16301269 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (EF; 15 mL of 1% ropivacaine plus 100 mug fentanyl)
Number of subjects: 45
Study 16301269 — intervention group
Group type: COMPARATOR
Intervention: IV fentanyl (IF; 15 mL of 1% ropivacaine plus 2 mL of normal saline followed by IV injection of 100 mug fentanyl)
Number of subjects: 45
Study 16301269 — intervention group
Group type: COMPARATOR
Intervention: Control (C; 15 mL of 1% ropivacaine plus 2 mL of normal saline followed by IV injection of 2 mL of normal saline)
Number of subjects: 45
Study 16301269 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (EF)
Number of subjects: 45
Study 16301269 — intervention group
Group type: COMPARATOR
Intervention: IV fentanyl (IF)
Number of subjects: 45
Study 16301269 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 45
Study 12184473 — intervention group
Group type: EXPERIMENTAL
Intervention: Available therapies for endometriosis
Number of subjects: 0
Study 9661568 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 150 micrograms
Number of subjects: 16
Study 9661568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8704435 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 62
Study 8704435 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 62
Study 2717292 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-crystal thermometer
Number of subjects: 503
Study 2717292 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet only
Number of subjects: 503
Study 2717292 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (thermometer and pamphlet)
Number of subjects: 503
Study 30955910 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage (30-minute session)
Number of subjects: 36
Study 30955910 — intervention group
Group type: COMPARATOR
Intervention: Control (no massage, only Sorenson test)
Number of subjects: 36
Study 30955910 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 36
Study 30955910 — intervention group
Group type: COMPARATOR
Intervention: Control (no massage)
Number of subjects: 36
Study 27916314 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided breast-conserving surgery (USS)
Number of subjects: 134
Study 27916314 — intervention group
Group type: COMPARATOR
Intervention: Palpation-guided surgery (PGS)
Number of subjects: 134
Study 27916314 — intervention group
Group type: EXPERIMENTAL
Intervention: USS
Number of subjects: 134
Study 27916314 — intervention group
Group type: COMPARATOR
Intervention: PGS
Number of subjects: 134
Study 25839348 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% diquafosol ophthalmic solution with high-WC CL
Number of subjects: 20
Study 25839348 — intervention group
Group type: COMPARATOR
Intervention: Saline with high-WC CL
Number of subjects: 20
Study 25839348 — intervention group
Group type: COMPARATOR
Intervention: 3% diquafosol ophthalmic solution with low-WC CL
Number of subjects: 20
Study 25839348 — intervention group
Group type: COMPARATOR
Intervention: Saline with low-WC CL
Number of subjects: 20
Study 25839348 — intervention group
Group type: COMPARATOR
Intervention: High-WC CL wear
Number of subjects: 20
Study 25839348 — intervention group
Group type: COMPARATOR
Intervention: Low-WC CL wear
Number of subjects: 20
Study 23643154 — intervention group
Group type: EXPERIMENTAL
Intervention: Group family planning counseling
Number of subjects: 0
Study 23643154 — intervention group
Group type: COMPARATOR
Intervention: Individual family planning counseling
Number of subjects: 0
Study 21537155 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 25 μg/hr
Number of subjects: 80
Study 21537155 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 50 μg/hr
Number of subjects: 80
Study 21537155 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 80
Study 19619203 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge transitional care programme (predischarge assessment, structured home visits, telephone follow-ups within four weeks after discharge)
Number of subjects: 200
Study 19619203 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge transitional care programme
Number of subjects: 200
Study 19619203 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 200
Study 17464158 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 12
Study 17464158 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 12
Study 17464158 — intervention group
Group type: COMPARATOR
Intervention: No-acupuncture waiting list condition
Number of subjects: 12
Study 16226163 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin, 80 mg
Number of subjects: 1825
Study 16226163 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin, 40 mg
Number of subjects: 1825
Study 12461368 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina-on-alumina ceramic bearing
Number of subjects: 0
Study 12461368 — intervention group
Group type: COMPARATOR
Intervention: Cobalt chrome-on-polyethylene bearing
Number of subjects: 0
Study 9861125 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 1.25 mg bolus at induction followed by droperidol 0.1 mg per 1 mg of morphine
Number of subjects: 60
Study 9861125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg bolus at induction followed by ondansetron 0.32 mg per 1 mg of morphine
Number of subjects: 60
Study 7652039 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light treatment (2500-3000 1x)
Number of subjects: 14
Study 7652039 — intervention group
Group type: EXPERIMENTAL
Intervention: Dim red light treatment (> 500 1x)
Number of subjects: 14
Study 7652039 — intervention group
Group type: COMPARATOR
Intervention: Night-shift work
Number of subjects: 14
Study 7652039 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-spectrum white light treatment
Number of subjects: 14
Study 7652039 — intervention group
Group type: EXPERIMENTAL
Intervention: Dim red light treatment
Number of subjects: 14
Study 2668253 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (200 mg) and amphotericin B (500 mg), twice daily
Number of subjects: 34
Study 2668253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 782701 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU plus adriamycin
Number of subjects: 13
Study 31028508 — intervention group
Group type: EXPERIMENTAL
Intervention: It's Your Game...Keep It Real! (IYG) intervention
Number of subjects: 1543
Study 31028508 — intervention group
Group type: COMPARATOR
Intervention: Usual care (comparison condition)
Number of subjects: 1543
Study 29392071 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal splint with airway
Number of subjects: 60
Study 29392071 — intervention group
Group type: COMPARATOR
Intervention: Merocel nasal packing
Number of subjects: 60
Study 27136909 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib pediatric oral solution
Number of subjects: 0
Study 27136909 — intervention group
Group type: COMPARATOR
Intervention: Tablet formulation of trametinib
Number of subjects: 0
Study 22561972 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg·kg(‐1) of body weight, administered 60 minutes before exercise)
Number of subjects: 5
Study 22561972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 21862954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (RBX) 32 mg/day
Number of subjects: 813
Study 21862954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 813
Study 19099919 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary thromboendarterectomy (PTE) therapy (Group A)
Number of subjects: 63
Study 19099919 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy (Group B)
Number of subjects: 63
Study 17299195 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-reduction group (n = 636)
Number of subjects: 1277
Study 17299195 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 641)
Number of subjects: 1277
Study 15082480 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 20 mg every other week
Number of subjects: 544
Study 15082480 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 20 mg weekly
Number of subjects: 544
Study 15082480 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 544
Study 15082480 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg weekly
Number of subjects: 544
Study 15082480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544